search
Back to results

Identification of Genetic Mutations Involved in Chiari Type I Malformations (ChiariGene)

Primary Purpose

Chiari Malformation, Type 1

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood Sample
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Chiari Malformation, Type 1 focused on measuring genetic mutation, syringomyelia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Having a social security
  • Participant or legal representative having given his consent
  • For patients: Diagnosis of a Chiari malformation type 1, defined morphologically as cerebellar tonsillar herniation beyond the foramen magnum greater than 5 mm, with or without associated syringomyelia, and which has at least one relating to the 1st or 2nd degree (parents, siblings; grandparents, uncles, aunts, cousins) carrying the malformation.
  • For relatives: at least two 1st degree relatives diagnosed with a Chiari type 1 malformation

Exclusion Criteria:

  • Syndromic form of Chiari malformation
  • Patient with a legal protection measure
  • Pregnant or breastfeeding woman
  • Contraindication to MRI
  • For patients: diagnosis of Chiari malformation type 1 that could not be confirmed by MRI
  • For relatives: age under 18 years

Sites / Locations

  • Service de Neurochirurgie

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Blood Sample

Arm Description

Blood Sample

Outcomes

Primary Outcome Measures

Identification of the gene (s) whose mutations are responsible for the occurrence of a Chiari type I malformation, whether associated with syringomyelia or not.
Description of gene mutations in patients with Chiari type I malformation by whole exome sequencing

Secondary Outcome Measures

Identification of the gene (s) whose mutations are associated with the occurrence of syringomyelia in patients with Chiari type I malformation
Description of gene mutations in patients with syringomyelia associated with Chiari type I malformation
Establishment of a DNA bank for familial Chiari type I malformations
Bio-collection

Full Information

First Posted
October 28, 2021
Last Updated
December 6, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT05165030
Brief Title
Identification of Genetic Mutations Involved in Chiari Type I Malformations
Acronym
ChiariGene
Official Title
Identification of Genetic Mutations Involved in Chiari Type I Malformations
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2022 (Anticipated)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Although most cases of Chiari malformation type I (CM1) are sporadic, familial cases of CM1, with or without syringomyelia, suggest a genetic cause in the pathogenesis of these malformations. The hypothesis is that there is one or more genes, in particular among those involved in the development of the axial skeleton and the cranium, which could lead to an abnormal morphology of the posterior fossa resulting in tonsillar herniation defining CM1. The abnormal circulation of cerebrospinal fluid due to tonsillar herniation is believed to be responsible, in some patients whose predisposing factors remain to be determined, for the progressive onset of associated syringomyelia. Since the determinants underlying the development of the posterior fossa of the skull are multigenic, the analysis of familial cases would make it possible to reduce genetic and phenotypic heterogeneity allowing to identify common pathogenic variants. For this study the investigators will be taking a blood sample to perform whole exome sequencing, build a biological collection and record imaging and clinical data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chiari Malformation, Type 1
Keywords
genetic mutation, syringomyelia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Blood sample for all participant during a consultation specific for the study
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Blood Sample
Arm Type
Experimental
Arm Description
Blood Sample
Intervention Type
Genetic
Intervention Name(s)
Blood Sample
Intervention Description
clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
Primary Outcome Measure Information:
Title
Identification of the gene (s) whose mutations are responsible for the occurrence of a Chiari type I malformation, whether associated with syringomyelia or not.
Description
Description of gene mutations in patients with Chiari type I malformation by whole exome sequencing
Time Frame
At inclusion (as soon as the patient agree)
Secondary Outcome Measure Information:
Title
Identification of the gene (s) whose mutations are associated with the occurrence of syringomyelia in patients with Chiari type I malformation
Description
Description of gene mutations in patients with syringomyelia associated with Chiari type I malformation
Time Frame
At inclusion (as soon as the patient agree)
Title
Establishment of a DNA bank for familial Chiari type I malformations
Description
Bio-collection
Time Frame
At inclusion (as soon as the patient agree)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Having a social security Participant or legal representative having given his consent For patients: Diagnosis of a Chiari malformation type 1, defined morphologically as cerebellar tonsillar herniation beyond the foramen magnum greater than 5 mm, with or without associated syringomyelia, and which has at least one relating to the 1st or 2nd degree (parents, siblings; grandparents, uncles, aunts, cousins) carrying the malformation. For relatives: at least two 1st degree relatives diagnosed with a Chiari type 1 malformation Exclusion Criteria: Syndromic form of Chiari malformation Patient with a legal protection measure Pregnant or breastfeeding woman Contraindication to MRI For patients: diagnosis of Chiari malformation type 1 that could not be confirmed by MRI For relatives: age under 18 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Steven Knafo
Phone
01 45 21 23 80
Email
steven.knafo@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Knafo
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Neurochirurgie
City
Le Kremlin Bicêtre
State/Province
Kremlin-Bicêtre
ZIP/Postal Code
94270
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Knafo
Phone
01 45 21 23 80
Email
steven.knafo@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Identification of Genetic Mutations Involved in Chiari Type I Malformations

We'll reach out to this number within 24 hrs